BIOMARIN PHARMACEUTICAL INC BMRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
7.43
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.2B | $348.9M | — | $725.0M | $6.1B |
| 2024 | $2.9B | $426.9M | — | $487.4M | $5.7B |
| 2023 | $2.4B | $167.6M | — | $62.6M | $5.0B |
| 2022 | $2.1B | $141.6M | — | $54.9M | $4.6B |
| 2021 | $1.8B | -$64.1M | — | $209.0M | $4.3B |
| 2020 | $1.9B | $854.0M | — | -$28.9M | $4.1B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Countouriotis Athena | director | 2026-06-02 | Grant | 7,490 | — |
| Walbert Timothy P | director | 2026-06-02 | Grant | 7,490 | — |
| Ho Maykin | director | 2026-06-02 | Grant | 7,490 | — |
| HOMBACH ROBERT J. | director | 2026-06-02 | Grant | 7,490 | — |
| Enyedy Mark J | director | 2026-06-02 | Grant | 7,490 | — |
| Dere Willard H | director | 2026-06-02 | Grant | 7,490 | — |
| CLARK IAN T | director | 2026-06-02 | Grant | 7,490 | — |
| Bodem Barbara W. | director | 2026-06-02 | Grant | 7,490 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.43 (safe)
- Working capital / assets 0.421
- Retained earnings / assets 0.02
- EBIT / assets 0.054
- Equity / liabilities 4.039
Source: SEC EDGAR filings · CIK 0001048477 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.